Meta description: Silk Road Medical, Inc. shares trade near their peak, showing strong investor interest. Key financial data and company profile outline the current position.
Company Overview
Silk Road Medical, Inc., founded in 2007 and headquartered in Sunnyvale, California, operates in the United States as a medical device company focused on enhancing treatment of carotid artery disease through transcarotid artery revascularization (TCAR). Its portfolio includes the ENROUTE Transcarotid Neuroprotection System, enabling direct access to the common carotid artery with temporary blood flow reversal, and ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent. Other specialized devices like the ENHANCE Transcarotid Peripheral Access Kit and ENROUTE 0.014 Guidewire support precision access and interventional navigation.
The company’s work addresses critical cardiovascular conditions with innovative technology aimed at improving patient safety and outcomes.
Current Stock Performance
As of the latest close, Silk Road Medical’s stock price stands at USD 27.49, slightly down by 0.01 points or -0.0364%. This places the share near its 52-week high of 27.51, and far above the 52-week low of 6.08. This range shows strong positive market movement from earlier lows, reflecting increased investor confidence.
Trading volume reached 2,308,974, well above the average daily volume of 1,132,687. High trading activity indicates heightened market interest and liquidity for the stock.
The absence of dividends (lastDividend: 0) means that Silk Road Medical currently channels earnings towards reinvestment and growth rather than direct shareholder payouts.
Market Position and Sector
Silk Road Medical’s market capitalization is approximately USD 1.12 billion, positioning the firm as a mid-cap player in the healthcare sector. Within the medical devices industry, the company competes with other firms focused on minimally invasive vascular interventions. The NASDAQ Global Select listing ensures compliance with strict corporate governance and financial standards, which supports investor trust.
Its specialization in TCAR technology differentiates it from general device manufacturers, giving it a niche advantage in a growing healthcare segment.
Governance and Leadership
Charles S. McKhann serves as the Chief Executive Officer, guiding the company’s strategic vision and operational execution. Under his leadership, Silk Road Medical has advanced its technology portfolio and expanded market presence. With a workforce of 474 full-time employees, the company maintains a balance between innovative research capacity and commercial reach.
Corporate contact details, including its Sunnyvale base at 1213 Innsbruck Drive, CA 94089, and direct line +1 408 720 9002, are publicly listed, aligning with transparency standards expected in the healthcare sector.
Key Financial Data
Price: USD 27.49
Market Cap: USD 1,116,976,429
Dividend: None
52-Week Range: 6.08 – 27.51
Change: -0.01 (-0.0364%)
Volume: 2,308,974 (average: 1,132,687)
For investors, these indicators offer a snapshot of Silk Road Medical’s liquidity, volatility, earnings strategy, and overall market valuation. The rise toward the top of its annual range signals strong upward momentum, while no dividend suggests a priority on reinvestment.
FAQ
- Does Silk Road Medical pay dividends? No. The company has not issued any dividend payments, focusing capital on growth initiatives.
- Where is Silk Road Medical traded? On the NASDAQ Global Select Market under ticker symbol SILK.
- What is the ISIN and CUSIP for the stock? ISIN: US82710M1009, CUSIP: 82710M100.
- How many employees does the company have? 474 full-time employees.
- When was the IPO? April 4, 2019.
Conclusion
Silk Road Medical’s current trading levels near its highest range reflect robust market engagement and optimism about its specialized device offerings. The high liquidity and steady market cap underscore investor interest, while leadership continuity reinforces operational stability. Stakeholders will watch for future financial disclosures to track how the reinvestment strategy impacts earnings growth.
Disclaimer
This article is for informational purposes only and does not constitute financial advice. Investors should conduct their own research or consult a financial advisor before making any investment decisions.
Official Source
For full information about the company, see the link below.